Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Number of holders
-
277
-
Total 13F shares, excl. options
-
83,028,261
-
Shares change
-
-194,062
-
Total reported value, excl. options
-
$4,393,785,594
-
Value change
-
+$179,415
-
Put/Call ratio
-
83%
-
Number of buys
-
131
-
Number of sells
-
119
-
Price
-
$52.92
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2022
As of 31 Dec 2022 Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) had 277 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 83,028,261 shares of stock of the company.
Largest 10 holders included FMR LLC, VANGUARD GROUP INC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, WASATCH ADVISORS INC, Bellevue Group AG, ALLIANCEBERNSTEIN L.P., STATE STREET CORP, FRANKLIN RESOURCES INC, and Invesco Ltd..
This table shows 281 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.